{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:39:10Z","timestamp":1788586750560,"version":"build-2803163510"},"reference-count":140,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The aetiology of many inflammatory cutaneous diseases is T cell\u2010driven and involves dysregulation of the immune response. The complex nature of the immune system's involvement in these diseases has made the development of effective, safe, and durable treatments challenging, resulting in a continued demand for the development of novel therapeutics. OX40 and its ligand OX40L have been previously identified as a crucial axis in T cell differentiation and function, and are promising targets for the treatment of T cell\u2010driven disease. Development of OX40\/OX40L agonists and inhibitors has potential uses in atopic dermatitis, alopecia areata, psoriasis, and more. While trials of these drugs have mainly been conducted in atopic dermatitis, they show promise in treating other dermatological conditions. Studies of amlitelimab and rocatinlimab have shown some efficacy but have demonstrated increased durability of response. Current concerns with the class are the potential for broad immune suppression with antagonists and the potential for worsening disease with agonists. Additional studies will enable us to determine their benefit\u2013risk ratio in the real\u2010world setting.<\/jats:p>","DOI":"10.1111\/jdv.70443","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T07:01:09Z","timestamp":1775890869000},"page":"1318-1331","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["<scp>OX40<\/scp>\n                    \/\n                    <scp>OX40L<\/scp>\n                    modulation: A target for regulating T cells in cutaneous inflammatory disorders"],"prefix":"10.1111","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8664-7723","authenticated-orcid":false,"given":"Aditya K.","family":"Gupta","sequence":"first","affiliation":[{"name":"Division of Dermatology, Department of Medicine, Temerty Faculty of Medicine University of Toronto  Toronto Ontario Canada"},{"name":"Mediprobe Research Inc  London Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Steriopoulos","sequence":"additional","affiliation":[{"name":"Mediprobe Research Inc  London Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Economopoulos","sequence":"additional","affiliation":[{"name":"Mediprobe Research Inc  London Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paradi","family":"Mirmirani","sequence":"additional","affiliation":[{"name":"Department of Dermatology The Permanente Medical Group  Vallejo California USA"},{"name":"Department of Dermatology University of California  San Francisco California USA"},{"name":"Department of Dermatology Case Western Reserve University  Cleveland Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Piguet","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, Temerty Faculty of Medicine University of Toronto  Toronto Ontario Canada"},{"name":"Division of Dermatology Department of Medicine, Women's College Hospital  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2020.10.023"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01918"},{"key":"e_1_2_13_4_1","unstructured":"AbbVie Inc.HUMIRA\u00ae (adalimumab) injection for subcutaneous use [Internet].2021. Available from:www.fda.gov\/medwatch"},{"key":"e_1_2_13_5_1","unstructured":"AbbVie Inc.SKYRIZI\u00ae (risankizumab\u2010rzaa) injection for subcutaneous or intravenous use [Internet].2024Available from:www.fda.gov\/medwatch"},{"key":"e_1_2_13_6_1","unstructured":"Johnson & Johnson.TREMFYA\u00ae (guselkumab) injection for subcutaneous or intravenous use [Internet].2025Available from:www.fda.gov\/medwatch"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.11.015"},{"key":"e_1_2_13_8_1","unstructured":"sanofi\u2010aventis US LLC.DUPIXENT\u00ae (dupilumab) injection for subcutaneous use [Internet].2025Available from:www.fda.gov\/medwatch"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.09.023"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-019-00742-7"},{"key":"e_1_2_13_11_1","unstructured":"Novartis Pharmaceuticals Corporation.COSENTYX\u00ae (secukinumab) injection for subcutaneous or intravenous use [Internet].2025Available from:www.fda.gov\/medwatch"},{"key":"e_1_2_13_12_1","unstructured":"Pfizer Laboratories Div Pfizer Inc.XELJANZ (tofacitinib) tablets for oral use; XELJANZ XR (tofacitinib) extended\u2010release tablets for oral use; XELJANZ (tofacitinib) Oral Solution [Internet].2025Available from:www.fda.gov\/medwatch"},{"key":"e_1_2_13_13_1","unstructured":"Eli Lilly and Company.HIGHLIGHTS OF PRESCRIBING INFORMATION \u2010 OLUMIANT \u2010baricitinib tablet film coated [Internet].2024Available from:www.fda.gov\/medwatch"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.07.019"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19426"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61112053"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.03.012"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevImmunol.v29.i3.10"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2022.11.009"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-015-8498-3"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.9.3338"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.670637"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14122753"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2017.01.006"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2009.00766.x"},{"issue":"7","key":"e_1_2_13_26_1","first-page":"979","article-title":"The upregulated expression of OX40\/OX40L and their promotion of T cells proliferation in the murine model of asthma","volume":"6","author":"Lei W","year":"2014","journal-title":"J Thorac Dis"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(01)00191-1"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2003.10.005"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003156"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.06.009"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-011-0965-4"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2005.03.012"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.652191"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4419-6451-9_5"},{"key":"e_1_2_13_35_1","doi-asserted-by":"crossref","unstructured":"PrellRA EvansDE ThalhoferC ShiT FunatakeC WeinbergAD.OX40\u2010mediated memory T cell generation is TNF receptor\u2010associated factor 2 dependent1 [Internet].2003Available from:www.ohsu","DOI":"10.4049\/jimmunol.171.11.5997"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.8.5014"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.6.3043"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1103586"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10122578"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2008.08.018"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.7.4464"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/1750743X.2025.2464528"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.11.053"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacig.2023.100195"},{"key":"e_1_2_13_45_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1321071111"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-024-01308-8"},{"key":"e_1_2_13_47_1","unstructured":"Kymab Limited.A Study of KY1005 in Patients With Moderate to Severe Atopic Dermatitis (NCT03754309) [Internet]. [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT03754309"},{"key":"e_1_2_13_48_1","unstructured":"Kymab Limited.Study testing response effect of KY1005 against moderate\u2010to\u2010severe atopic dermatitis the STREAM\u2010AD Study (STREAM\u2010AD) (NCT05131477). [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT05131477"},{"key":"e_1_2_13_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02037-2"},{"key":"e_1_2_13_50_1","doi-asserted-by":"publisher","DOI":"10.4110\/in.2022.22.e7"},{"key":"e_1_2_13_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-021-08883-0"},{"key":"e_1_2_13_52_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1641918"},{"key":"e_1_2_13_53_1","first-page":"119","volume-title":"Procedures in cosmetic dermatology: hair restoration","author":"Benton S","year":"2023"},{"key":"e_1_2_13_54_1","first-page":"106","volume-title":"Procedures in cosmetic dermatology: hair restoration","author":"Truong C","year":"2023"},{"key":"e_1_2_13_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.06.097"},{"key":"e_1_2_13_56_1","unstructured":"Pfizer Labs.LITFULO\u2010TM (ritlecitinib) capsules for oral use [Internet].2023Available from:www.fda.gov\/medwatch"},{"key":"e_1_2_13_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.16268"},{"key":"e_1_2_13_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.70157"},{"key":"e_1_2_13_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14254"},{"key":"e_1_2_13_60_1","doi-asserted-by":"publisher","DOI":"10.3906\/sag-1807-230"},{"key":"e_1_2_13_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00752-6"},{"key":"e_1_2_13_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2025.04.016"},{"key":"e_1_2_13_63_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljaf041"},{"key":"e_1_2_13_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02475-9"},{"key":"e_1_2_13_65_1","unstructured":"UCB Inc.BIMZELX (bimekizumab\u2010bkzx) injection for subcutaneous use [Internet].2024Available from:www.fda.gov\/medwatch"},{"key":"e_1_2_13_66_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.717042"},{"key":"e_1_2_13_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacig.2025.100483"},{"key":"e_1_2_13_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14313"},{"key":"e_1_2_13_69_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00838-9"},{"key":"e_1_2_13_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109805"},{"key":"e_1_2_13_71_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202551820"},{"key":"e_1_2_13_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2025.501198"},{"key":"e_1_2_13_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.16243"},{"key":"e_1_2_13_74_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2026763118"},{"key":"e_1_2_13_75_1","unstructured":"Sanofi.A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata (NCT06444451). [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT06444451"},{"key":"e_1_2_13_76_1","unstructured":"Sanofi.Proof\u2010of\u2010concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa (NCT06118099). [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT06118099"},{"key":"e_1_2_13_77_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad240"},{"key":"e_1_2_13_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.10.031"},{"key":"e_1_2_13_79_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20877"},{"key":"e_1_2_13_80_1","unstructured":"Sanofi.Long\u2010term safety and efficacy evaluation of subcutaneous amlitelimab in adult participants with moderate\u2010to\u2010severe asthma who completed treatment period of previous amlitelimab asthma clinical study (RIVER\u2010ASTHMA) (NCT06033833). [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT06033833"},{"key":"e_1_2_13_81_1","unstructured":"Sanofi.Long\u2010term safety and efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinical trials (RIVER\u2010AD) (NCT05492578). [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT05492578"},{"key":"e_1_2_13_82_1","unstructured":"Sanofi.Dose ranging study of amlitelimab in adult participants with moderate\u2010to\u2010severe asthma (TIDE\u2010asthma) (NCT05421598). [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT05421598"},{"key":"e_1_2_13_83_1","unstructured":"Sanofi.Open label long\u2010term study evaluating safety and efficacy of subcutaneous amlitelimab in participants aged 12\u2009years and older with moderate to severe atopic dermatitis (ATLANTIS) (NCT05769777) [Internet]. [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT05769777"},{"key":"e_1_2_13_84_1","unstructured":"Sanofi.A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in participants aged 12\u2009years and older with moderate\u2010to\u2010severe atopic dermatitis (COAST 1) (NCT06130566). [cited 2025 Aug 24]; Available from:https:\/\/clinicaltrials.gov\/study\/NCT06130566"},{"key":"e_1_2_13_85_1","unstructured":"Sanofi.A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in participants aged 12\u2009years and older with moderate\u2010to\u2010severe atopic dermatitis (COAST 2) (NCT06181435). [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT06181435"},{"key":"e_1_2_13_86_1","unstructured":"Sanofi.A study to evaluate the efficacy and safety of subcutaneous amlitelimab in participants aged 12\u2009years and older with moderate\u2010to\u2010severe atopic dermatitis on background topical corticosteroids (SHORE) (NCT06224348). [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT06224348"},{"key":"e_1_2_13_87_1","unstructured":"Sanofi.A phase 2a\/b study of the efficacy and safety of subcutaneous amlitelimab in adults with nonresponsive celiac disease (NCT06557772). [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT06557772"},{"key":"e_1_2_13_88_1","unstructured":"Sanofi.A study to evaluate the efficacy and safety of subcutaneous amlitelimab on background topical corticosteroids therapy in participants aged 12\u2009years and older with moderate\u2010to\u2010severe AD who have had an inadequate response to prior biologic therapy or an oral JAK inhibitor (AQUA) (NCT06241118). [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT06241118"},{"key":"e_1_2_13_89_1","unstructured":"Sanofi.A study to evaluate the treatment response and safety of two dose regimens of subcutaneous amlitelimab compared with treatment withdrawal in participants aged 12\u2009years and older with moderate\u2010to\u2010severe atopic dermatitis (ESTUARY) (NCT06407934). [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT06407934"},{"key":"e_1_2_13_90_1","unstructured":"Oxion Biologics AB.A first\u2010in\u2010human phase I trial of OX118 in healthy volunteers (NCT07020156). [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT07020156"},{"key":"e_1_2_13_91_1","unstructured":"Amgen.A study assessing rocatinlimab (AMG 451) monotherapy in moderate\u2010to\u2010severe atopic dermatitis (AD) (ROCKET\u2010Horizon) (ROCKET\u2010Horizon) (NCT05651711). [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT05651711"},{"key":"e_1_2_13_92_1","unstructured":"Amgen.A study assessing rocatinlimab in combination with topical corticosteroid and\/or topical calcineurin inhibitors in adult participants with moderate\u2010to\u2010severe atopic dermatitis (AD) (ROCKET\u2010SHUTTLE) (NCT05724199). [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT05724199"},{"key":"e_1_2_13_93_1","unstructured":"Amgen.A study assessing rocatinlimab on vaccine antibody response in moderate\u2010to\u2010severe atopic dermatitis (AD) (ROCKET \u2010 VOYAGER) (ROCKET\u2010VOYAGER) (NCT05899816) [Internet]. [cited 2025 Aug 24]. Available from:https:\/\/www.clinicaltrials.gov\/study\/NCT05899816"},{"key":"e_1_2_13_94_1","unstructured":"Amgen.A study evaluating rocatinlimab in moderate\u2010to\u2010severe atopic dermatitis (ROCKET\u2010IGNITE) (ROCKET\u2010Ignite) (NCT05398445). [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT05398445"},{"key":"e_1_2_13_95_1","unstructured":"Amgen.A study to assess long\u2010term safety tolerability and efficacy of rocatinlimab in adult and adolescent participants with moderate\u2010to\u2010severe atopic dermatitis (AD) (ROCKET\u2010ASCEND) (NCT05882877). [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT05882877"},{"key":"e_1_2_13_96_1","unstructured":"Amgen.A study to assess the safety tolerability and efficacy of rocatinlimab in adolescent participants with moderate\u2010to\u2010severe atopic dermatitis (AD) (ROCKET\u2010Orbit) (NCT05633355). [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT05633355"},{"key":"e_1_2_13_97_1","unstructured":"Amgen.A study to evaluate rocatinlimab (AMG 451) in adolescent participants with moderate\u2010to\u2010severe atopic dermatitis (AD) (ROCKET\u2010ASTRO) (NCT05704738). [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT05704738"},{"key":"e_1_2_13_98_1","unstructured":"Amgen.A study with self\u2010administered rocatinlimab in adolescent and adult participants with moderate\u2010to\u2010severe atopic dermatitis (ROCKET\u2010outpost) (NCT06224192). [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT06224192"},{"key":"e_1_2_13_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2020.06.005"},{"key":"e_1_2_13_100_1","unstructured":"Amgen.A phase 2 dose ranging study assessing rocatinlimab in moderate\u2010to\u2010severe asthma (NCT06376045). [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT06376045"},{"key":"e_1_2_13_101_1","unstructured":"Amgen.A phase 3 placebo\u2010controlled double\u2010blind study assessing rocatinlimab in prurigo nodularis (NCT06527404). [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT06527404"},{"key":"e_1_2_13_102_1","unstructured":"Bio\u2010Thera Solutions.Evaluate the safety tolerability of BAT6026 (NCT06094179). [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT06094179"},{"key":"e_1_2_13_103_1","unstructured":"Bio\u2010Thera Solutions.Assessment of safety and preliminary efficacy with BAT6026 in solid tumor patients in China (NCT05105971). [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT05105971"},{"key":"e_1_2_13_104_1","unstructured":"Bio\u2010Thera Solutions.Assessment of safety and preliminary efficacy with BAT6026 in solid tumour patients (NCT05109650). [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT05109650"},{"key":"e_1_2_13_105_1","unstructured":"BeiGene.Safety and preliminary effectiveness of BGB\u2010A445 in combination with tislelizumab in participants with advanced solid tumors (NCT04215978). [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT04215978"},{"key":"e_1_2_13_106_1","unstructured":"BeiGene.A study to investigate the antitumor activity safety tolerability and pharmacokinetics of BGB\u2010A445 in combination with tislelizumab in participants with select advanced solid tumors (NCT05661955). [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT05661955"},{"key":"e_1_2_13_107_1","unstructured":"BeiGene.A study of BGB\u2010A445 in combination with other investigational agents in participants with non\u2010small cell lung cancer (NCT06029127). [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT06029127"},{"key":"e_1_2_13_108_1","unstructured":"Bristol Myers Squibb.An investigational immuno\u2010therapy study of experimental medication BMS\u2010986178 by itself or in combination with nivolumab and\/or ipilimumab in participants with solid cancers that are advanced or have spread (NCT02737475). [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT02737475"},{"key":"e_1_2_13_109_1","unstructured":"LevyR.SD\u2010101 and BMS\u2010986178 in treating patients with advanced or metastatic solid malignancies (NCT03831295). [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT03831295"},{"key":"e_1_2_13_110_1","unstructured":"Shanghai Henlius Biotech.Evaluate the safety tolerability and pharmacokinetic characteristics of HLX51 in patients with solid tumor or lymphoma (NCT05788107). [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT05788107"},{"key":"e_1_2_13_111_1","unstructured":"Inhibrx Biosciences.INBRX\u2010106 in Combination With Pembrolizumab in First\u2010line PD\u2010L1 CPS\u226520 HNSCC (HexAgon\u2010HN) (NCT06295731). [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT06295731"},{"key":"e_1_2_13_112_1","unstructured":"Inhibrx Biosciences.Study of INBRX\u2010106 and INBRX\u2010106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) (NCT04198766). [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT04198766"},{"key":"e_1_2_13_113_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011524"},{"key":"e_1_2_13_114_1","unstructured":"Elpiscience Biopharma.A study of ES102 (OX40 agonist) in patients with advanced solid tumors (NCT04730843). [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT04730843"},{"key":"e_1_2_13_115_1","unstructured":"Elpiscience Biopharma.A study of ES102 (OX40 Agonist) in combination with JS001 in patients with advanced solid tumors (NCT04991506). [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT04991506"},{"key":"e_1_2_13_116_1","unstructured":"Elpiscience (Suzhou) Biopharma.A study of ES102 in combination with toripalimab in subjects with advanced non\u2010small cell lung cancer (NCT06623136). [cited 2025 Aug 24].Available from:https:\/\/clinicaltrials.gov\/study\/NCT06623136"},{"key":"e_1_2_13_117_1","unstructured":"Providence Health & Services.Neoadjuvant INBRX\u2010106 (hexavalent OX40 agonist) in combination with pembrolizumab as a chemotherapy\u2010sparing regimen for stage II TNBC (triple negative breast cancer) patients (NCT06353997). [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT06353997"},{"key":"e_1_2_13_118_1","unstructured":"Pfizer.Study Of OX40 agonist PF\u201004518600 alone and in combination with 4\u20101BB agonist PF\u201005082566 (NCT02315066) [Internet]. [cited 2025 Aug 25]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT02315066"},{"key":"e_1_2_13_119_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0845"},{"key":"e_1_2_13_120_1","unstructured":"Pfizer.Continued access study for participants deriving benefit in pfizer\u2010sponsored avelumab parent studies that are closing (NCT05059522). [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT05059522"},{"key":"e_1_2_13_121_1","unstructured":"Pfizer.A study of avelumab in combination with other cancer immunotherapies in advanced malignancies (JAVELIN Medley) (NCT02554812) [Internet]. [cited 2025 Aug 25]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT02554812"},{"key":"e_1_2_13_122_1","unstructured":"Sanofi.Open Label Long\u2010term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12\u2009Years and Older With Moderate to Severe Atopic Dermatitis (ATLANTIS) (NCT05769777) [Internet]. [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT05769777"},{"key":"e_1_2_13_123_1","unstructured":"Sanofi.A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12\u2009Years and Older With Moderate\u2010to\u2010severe Atopic Dermatitis (COAST 1) (NCT06130566). [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT06130566"},{"key":"e_1_2_13_124_1","unstructured":"Sanofi.A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12\u2009Years and Older With Moderate\u2010to\u2010severe Atopic Dermatitis (COAST 2) (NCT06181435). [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT06181435"},{"key":"e_1_2_13_125_1","unstructured":"Sanofi.A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12\u2009Years and Older With Moderate\u2010to\u2010severe Atopic Dermatitis (ESTUARY) (NCT06407934). [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT06407934"},{"key":"e_1_2_13_126_1","unstructured":"Sanofi.A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12\u2009Years and Older With Moderate\u2010to\u2010severe Atopic Dermatitis on Background Topical Corticosteroids (SHORE) (NCT06224348). [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT06224348"},{"key":"e_1_2_13_127_1","unstructured":"Long\u2010Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials (RIVER\u2010AD) (NCT05492578). [cited 2025 Aug 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT05492578"},{"key":"e_1_2_13_128_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01609-6"},{"key":"e_1_2_13_129_1","volume-title":"Press release: Sanofi's amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis [Internet]","author":"Sanofi","year":"2025"},{"key":"e_1_2_13_130_1","doi-asserted-by":"publisher","DOI":"10.3345\/cep.2024.00339"},{"key":"e_1_2_13_131_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01865-3"},{"key":"e_1_2_13_132_1","unstructured":"Amgen Kyowa Kirin.Amgen and Kyowa Kirin announce top\u2010line results from rocatinlimab phase 3 ascend long\u2010term extension study in adults with moderate to severe atopic dermatitis.2025Available from:https:\/\/www.amgen.com\/newsroom\/press\u2010releases\/2025\/09\/amgen\u2010and\u2010kyowa\u2010kirin\u2010announce\u2010top\u2010line\u2010results\u2010from\u2010rocatinlimab\u2010phase\u20103\u2010ascend\u2010long\u2010term\u2010extension\u2010study\u2010in\u2010adults\u2010with\u2010moderate\u2010to\u2010severe\u2010atopic\u2010dermatitis"},{"key":"e_1_2_13_133_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-025-04809-1"},{"key":"e_1_2_13_134_1","unstructured":"Henlius.Press release: henlius novel anti\u2010OX40 HLX51 received clinical trial approval in china [Internet].2023[cited 2025 Oct 30]. Available from:https:\/\/www.henlius.com\/en\/NewsDetails\u20104038\u201026.html"},{"key":"e_1_2_13_135_1","unstructured":"University of Southern California.Axitinib with or without anti\u2010OX40 antibody PF\u201004518600 in treating patients with metastatic kidney cancer (NCT03092856) [Internet]; [cited 2025 Aug 25]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT03092856"},{"key":"e_1_2_13_136_1","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v105.43608"},{"key":"e_1_2_13_137_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13226925"},{"key":"e_1_2_13_138_1","doi-asserted-by":"publisher","DOI":"10.1007\/s42995-025-00284-y"},{"key":"e_1_2_13_139_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20130592"},{"key":"e_1_2_13_140_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2015.00034"},{"key":"e_1_2_13_141_1","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S511125"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70443","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.70443","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70443","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:59:36Z","timestamp":1785499176000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.70443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":140,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1111\/jdv.70443"],"URL":"https:\/\/doi.org\/10.1111\/jdv.70443","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"2025-09-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}